{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:33:05Z","timestamp":1778923985569,"version":"3.51.4"},"reference-count":124,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is still considered an incurable hematologic cancer and, in the last decades, the treatment goal has been to obtain a long-lasting disease control. However, the recent availability of new effective drugs has led to unprecedented high-quality responses and prolonged progression-free survival and overall survival. The improvement of response rates has prompted the development of new, very sensitive methods to measure residual disease, even when monoclonal components become undetectable in patients\u2019 serum and urine. Several scientific efforts have been made to develop reliable and validated techniques to measure minimal residual disease (MRD), both within and outside the bone marrow. With the newest multidrug combinations, a good proportion of MM patients can achieve MRD negativity. Long-lasting MRD negativity may prove to be a marker of \u201coperational cure\u201d, although the follow-up of the currently ongoing studies is still too short to draw conclusions. In this article, we focus on results obtained with new-generation multidrug combinations in the treatment of high-risk smoldering MM and newly diagnosed MM, including the potential role of MRD and MRD-driven treatment strategies in clinical trials, in order to optimize and individualize treatment.<\/jats:p>","DOI":"10.3390\/cancers11122015","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T11:27:22Z","timestamp":1576236442000},"page":"2015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies"],"prefix":"10.3390","volume":"11","author":[{"given":"Mattia","family":"D'Agostino","sequence":"first","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Oliva","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nandakumar, B., Binder, M., Dispenzieri, A., Kapoor, P., Buadi, F., Gertz, M.A., Lacy, M., Dingli, D., Hwa, L., and Leung, N. (2019). Continued improvement in survival in multiple myeloma (MM) including high-risk patients. J. Clin. Oncol., 37, Abstract #8039 [ASCO 2019 Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.8039"},{"key":"ref_4","first-page":"35","article-title":"Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987\u20132013","volume":"146","author":"Birmann","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau, H., Moreau, P., Attal, M., Hulin, C., Arnulf, B., Corre, J., Garderet, L., Karlin, L., Lambert, J., and Macro, M. (2019). Efficacy of daratumumab (DARA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. J. Clin. Oncol., 37, Abstract #8017 [ASCO 2019 International Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.8017"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zimmerman, T., Raje, N.S., Vij, R., Reece, D., Berdeja, J.G., Stephens, L.A., McDonnell, K., Rosenbaum, C.A., Jasielec, J., and Richardson, P.G. (2016). Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 128, Abstract #675 [ASH 2016 58th Meeting].","DOI":"10.1182\/blood.V128.22.675.675"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gay, F., Cerrato, C., Petrucci, M.T., Zambello, R., Gamberi, B., Ballanti, S., Omed\u00e8, P., Palmieri, S., Troia, R., and Spada, S. (2019). Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the forte trial. J. Clin. Oncol., 37, Abstract #8002 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.8002"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Voorhees, P.M., Rodriguez, C., Reeves, B., Nathwani, N., Costa, L.J., Lutska, Y., Hoehn, D., Pei, H., Ukropec, J., and Qi, M. (2018). Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D.; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple, M. Blood, 132, Abstract #151 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-151"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jakubowiak, A.J., Chari, A., Lonial, S., Weiss, B.M., Comenzo, R.L., Wu, K., Khokhar, N.Z., Wang, J., Doshi, P., and Usmani, S.Z. (2017). Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. J. Clin. Oncol., 35, Abstract #8000 [ASCO 2017 Annual Meeting].","DOI":"10.1200\/JCO.2017.35.15_suppl.8000"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: A new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytometry Part B Clin. Cytom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytometry Part B Clin. Cytom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_21","unstructured":"FDA (2019, October 23). Authorizes First Next Generation Sequencing-Based Test to Detect Very Low Levels of Remaining Cancer Cells in Patients with Acute Lymphoblastic Leukemia or Multiple Myeloma, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"ref_24","unstructured":"Avet-Loiseau, H., Bene, M.C., Wuilleme, S., Corre, J., Attal, M., Arnulf, B., Garderet, L., Macro, M., Stoppa, A.-M., and Delforge, M. (2019, January 12\u201315). Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA. Proceedings of the 17th International Myeloma Workshop, Boston, MA, USA. [Abstract #OAB\u2013004]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Oliva, S., op Bruinink, D.H., \u0158\u00cdhov\u00e1, L., Spada, S., van der Holt, B., Troia, R., Gambella, M., Pantani, L., Grammatico, S., and Gilestro, M. (2017). Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02\/HO95 phase 3 trial. J. Clin. Oncol., 35.","DOI":"10.1200\/JCO.2017.35.15_suppl.8011"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Paiva, B., Puig, N., Cedena, M.T., Cordon, L., Vidriales, M.-B., Burgos, L., Flores-Montero, J., Lopez-Anglada, L., Gutierrez, N., and Calasanz, M.J. (2017). Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema\/GEM2012 Trial. Blood, 130, Abstract #905 [ASH 2017 58th Meeting].","DOI":"10.1182\/blood.V130.Suppl_1.905.905"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Cibeira","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1182\/blood-2011-09-379818","article-title":"PET-CT in MM: A new definition of CR","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zamagni, E., Nanni, C., Dozza, L., Carlier, T., Tacchetti, P., Versari, A., Chauvie, S., Gallamini, A., Attal, M., and Gamberi, B. (2018). Standardization of 18F-FDG PET\/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 132, Abstract #257 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-111321"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau, H., San-Miguel, J.F., Casneuf, T., Iida, S., Lonial, S., Usmani, S.Z., Spencer, A., Moreau, P., Plesner, T., and Weisel, K. (2018). Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed\/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): An. Blood, 132, Abstract #3272 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-113177"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019","volume":"16","author":"Radich","year":"2018","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal Flow Cytometry Identified \u201cMinimal Residual Disease\u201d (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lakshman, A., Vincent Rajkumar, S., Buadi, F.K., Binder, M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Dingli, D., Fonder, A.L., and Hayman, S.R. (2018). Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J., 8.","DOI":"10.1038\/s41408-018-0077-4"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: Results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Proc. Leuk. Lymphoma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Vidriales","year":"2007","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"San Miguel, J., Mateos, M.-V., Gonzalez, V., Dimopoulos, M.A., Kastritis, E., Hajek, R., de Larrea Rodr\u00edguez, C., Morgan, G.J., Merlini, G., and Mangiacavalli, S. (2019). Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J. Clin. Oncol., 37, Updated data presented at the meeting.","DOI":"10.1200\/JCO.2019.37.15_suppl.8000"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"Vidriales","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.HS9.0000561764.53887.c0","article-title":"Curative strategy (gem-cesar) for high-risk smoldering myeloma: Carfilzomib, lenalidomide and dexamethasone (krd) as induction followed by hdt-asct, consolidation with krd and maintenance with rd","volume":"3","author":"Mateos","year":"2019","journal-title":"HemaSphere"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mailankody, S., Salcedo, M., Tavitian, E., Korde, N., Lendvai, N., Hassoun, H., Lesokhin, A.M., Lahoud, O.B., Smith, E.L., and Hultcrantz, M. (2019). Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study. J. Clin. Oncol., 37, Abstract #8051 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.8051"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: A phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Liu, C., Ghobrial, I.M., Bustoros, M., Reyes, K., Hornburg, K., Badros, A.Z., Vredenburgh, J.J., Boruchov, A., Matous, J.V., and Caola, A. (2018). Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 132, Abstract #154 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-154"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bustoros, M., Liu, C., Reyes, K., Hornburg, K., Guimond, K., Styles, R., Savell, A., Berrios, B., Warren, D., and Dumke, H. (2018). Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 132, Abstract #804 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-117871"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Landgren, O., Cavo, M., Chari, A., Cohen, Y.C., Spencer, A., Voorhees, P.M., Estell, J., Sandhu, I., Jenner, M., and Williams, C. (2018). Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 132, Abstract #1994 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-113467"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Voorhees, P.M., Goldschmidt, H., Baker, R.I., Bandekar, R., Kuppens, S., Neff, T., Qi, M., and Dimopoulos, M.A. (2018). Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. J. Clin. Oncol., 36, Abstract #TPS8062 (ASCO 2018 Annual Meeting].","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8062"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R.Z., Kaufman, J.L., Yacoub, A.M., Buadi, F.K., and O\u2019Brien, T. (2019). Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J. Clin. Oncol., 37, Abstract #8001 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.8001"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Yaccoby, S., Zangari, M., Heuck, C., Hoering, A., Morgan, G.J., and Crowley, J. (2014). Curing Multiple Myeloma (MM) with Total Therapy (TT). Blood, 124, Abstract #195 [ASH 2014 56th Meeting].","DOI":"10.1182\/blood.V124.21.195.195"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Pawlyn, C., Davies, F., Cairns, D., Striha, A., Hockaday, A., Kishore, B., Garg, M., Williams, C., Karunanithi7, K., and Lindsay, J. (2019, January 12\u201315). Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients. Proceedings of the International Myeloma Workshop, Boston, MA, USA. [Abstract #OAB\u2013002]. Updated data presented at the meeting.","DOI":"10.1016\/j.clml.2019.09.003"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jackson, G.H., Davies, F.E., Pawlyn, C., Cairns, D., Striha, A., Hockaday, A., Collett, C., Jones, J.R., Kishore, B., and Garg, M. (2018). A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD\/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. Blood, 132, Abstract #302 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-114956"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_75","unstructured":"Rosinol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M.J., Hern\u00e1ndez, M.T., Mart\u00ednez-Mart\u00ednez, R., Moraleda, J.M., Jarque, I., and Bargay, J. (2017). Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema\/GEM Trial. Blood, 130, Abstract #2017 [ASH 2017 59th Annual Meeting]."},{"key":"ref_76","unstructured":"Voorhees, P., Kaufman, J.L., Laubach, J., Sborov, D., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L., and Anderson, L. (2019, January 12\u201315). Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. Proceedings of the 17th International Myeloma Workshop, Boston, MA, USA. [Abstract #OAB\u201387]."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rosi\u00f1ol Dachs, L., Hebraud, B., Oriol, A., Colin, A.-L., Rios, R., Hulin, C., Blanchard, M.J., Caillot, D., Sureda, A., and Hern\u00e1ndez, M.T. (2018). Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood, 132, Abstract #3245 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-112659"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_81","unstructured":"Cavo, M., H\u00e1jek, R., Pantani, L., Beksac, M., Oliva, S., Dozza, L., Johnsen, H.E., Petrucci, M.T., Mellqvist, U.-H., and Conticello, C. (2017). Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02\/HO95 Study. Blood, 130, Abstract #397 [ASH 2017 59th Meeting]."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Cavo, M., Goldschmidt, H., Rosinol, L., Pantani, L., Zweegman, S., Salwender, H.J., Lahuerta, J.J., Lokhorst, H.M., Petrucci, M.T., and Blau, I. (2018). Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. Blood, 132, Abstract #124 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-112899"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_84","first-page":"5","article-title":"Consolidation followed by maintenance vs maintenance alone in newly diagnosed, transplant eligible multiple myeloma: A randomized phase 3 study of the european myeloma network (emn02\/ho95 mm trial)","volume":"2","author":"Sonneveld","year":"2018","journal-title":"HemaSphere"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Oliva, S., Gambella, M., Larocca, A., Spada, S., Marzanati, E., Mantoan, B., Grammatico, S., Conticello, C., Gamberi, B., and Offidani, M. (2016). Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy. Blood, 128, Abstract #4409 [ASH 2016 58th Meeting].","DOI":"10.1182\/blood.V128.22.4409.4409"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omed\u00e9, P., Ronconi, S., Cangialosi, C., and Podda, L. (2019). Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers, 11.","DOI":"10.3390\/cancers11111735"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/cncr.30366","article-title":"Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"122","author":"Mian","year":"2016","journal-title":"Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: Long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2018.09.008","article-title":"Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials","volume":"132","author":"Conticello","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance Treatment and Survival in Patients With Myeloma","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_94","unstructured":"D\u2019Agostino, M., Zaccaria, G.M., Ziccheddu, B., Genuardi, E., Maura, F., Oliva, S., Auclair, D., Yesil, J., Capra, A., and Colucci, P. (2019, January 12\u201315). Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study. Proceedings of the 17 th International Myeloma Workshop, Boston, MA, USA. [Abstract #OAB\u2013018]."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"ref_97","first-page":"1","article-title":"Improved Efficacy After Incorporating Autologous Stem Cell Transplant (Asct) Into Krd Treatment With Carfilzomib (Cfz), Lenalidomide (Len), And Dexamethasone (Dex) In Newly Diagnosed Multiple Myeloma","volume":"101","author":"Jakubowiak","year":"2016","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Roussel, M., Lauwers-Cances, V., Robillard, N., Belhadj, K., Facon, T., Garderet, L., Escoffre, M., Pegourie, B., Benboubker, L., and Caillot, D. (2016). Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of th. Blood, 128, Abstract #1142 [ASH 2017 59th Meeting].","DOI":"10.1182\/blood.V128.22.1142.1142"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Gay, F., Cerrato, C., Scalabrini, D.R., Galli, M., Belotti, A., Zamagni, E., Ledda, A., Grasso, M., Angelucci, E., and Liberati, A.M. (2018). Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized FORTE Trial in Newly Di. Blood, 132, Abstract #121 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-112093"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Weisel, K., Asemissen, A.M., Schieferdecker, A., Besemer, B., Zago, M., Mann, C., Lutz, R., Benner, A., Tichy, D., and Bokemeyer, C. (2019, January 12\u201315). Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial. Proceedings of the International Myeloma Workshop, Boston, MA, USA. [Abstract #OAB\u2013023].","DOI":"10.1016\/j.clml.2019.09.024"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Bringhen, S., D\u2019Agostino, M., Paris, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota-Scalabrini, D., and De Rosa, L. (2019). Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: Updated results of the EMN01 randomized trial. Haematologica, [ahead of print].","DOI":"10.3324\/haematol.2019.226407"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2018.1496823","article-title":"Determining treatment intensity in elderly patients with multiple myeloma","volume":"18","author":"Salvini","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma","volume":"31","author":"Schlag","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Larocca, A., Salvini, M., De Paoli, L., Cascavilla, N., Benevolo, G., Galli, M., Montefusco, V., di Toritto, T.C., Baraldi, A., and Spada, S. (2018). Efficacy and Feasibility of Dose\/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. Blood, 132, Abstract #305 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-111796"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"Laubach","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ocio, E.M., Otero, P.R., Bringhen, S., Oliva, S., Nogai, A., Attal, M., Moreau, P., Kanagavel, D., Fitzmaurice, T., and Wu, J. (2018). Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. Blood, 132, Abstract #595 [ASH 2018 60th Meeting].","DOI":"10.1182\/blood-2018-99-111244"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood-2015-02-626168","article-title":"Phase 1\/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: A multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/leu.2017.327","article-title":"Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma","volume":"32","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3324\/haematol.2018.208272","article-title":"Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase I\/II studies","volume":"104","author":"Bringhen","year":"2019","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: Implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/acg2.26","article-title":"Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018","volume":"2","author":"Landgren","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/12\/2015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:42:09Z","timestamp":1760190129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/12\/2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":124,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["cancers11122015"],"URL":"https:\/\/doi.org\/10.3390\/cancers11122015","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]}}}